Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226736 | 0.86 | NPC1 (0.44) | MAOAMAOBNPC1RAB9AL3MBTL1 | |
| SCHEMBL512905 | 0.84 | RAB9A (0.51) | HTR7MAOBNPC1RAB9AL3MBTL1 | |
| SCHEMBL11870167 | 0.76 | NPC1 (0.58) | MAOAMAOBNPC1RAB9AL3MBTL1 | |
| SCHEMBL8244818 | 0.74 | NR1H4 (0.67) | GRM5PLAT | |
| SCHEMBL4226589 | 0.74 | RAB9A (0.44) | MAOAMAOBNPC1RAB9AL3MBTL1 | |
| SCHEMBL4222139 | 0.74 | NPC1 (0.44) | MAOAMAOBNPC1RAB9AGRM5 | |
| SCHEMBL513325 | 0.74 | KCNH2 (0.49) | GRM5KMT2A | |
| Hydrochloric Acid SCHEMBL5331967 | 0.73 | NR1H4 (0.65) | GRM5PLAT | |
| SCHEMBL4223486 | 0.72 | NPC1 (0.42) | MAOAMAOBNPC1RAB9AGRM5 | |
| SCHEMBL513914 | 0.72 | GRM5 (0.41) | NPC1GRM5MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | HTR7 198/4885MAOA 412/4885MAOB 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.